Logo image of LSTA

LISATA THERAPEUTICS INC (LSTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LSTA - US1280583022 - Common Stock

1.94 USD
-0.01 (-0.51%)
Last: 12/9/2025, 1:56:52 PM
Fundamental Rating

2

LSTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While LSTA seems to be doing ok healthwise, there are quite some concerns on its profitability. LSTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LSTA has reported negative net income.
In the past year LSTA has reported a negative cash flow from operations.
LSTA had negative earnings in each of the past 5 years.
LSTA had a negative operating cash flow in each of the past 5 years.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

LSTA has a Return On Assets of -75.21%. This is in the lower half of the industry: LSTA underperforms 64.78% of its industry peers.
LSTA has a Return On Equity (-89.99%) which is in line with its industry peers.
Industry RankSector Rank
ROA -75.21%
ROE -89.99%
ROIC N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

LSTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LSTA has more shares outstanding than it did 1 year ago.
LSTA has more shares outstanding than it did 5 years ago.
LSTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

LSTA has an Altman-Z score of -30.25. This is a bad value and indicates that LSTA is not financially healthy and even has some risk of bankruptcy.
LSTA has a Altman-Z score of -30.25. This is amonst the worse of the industry: LSTA underperforms 89.64% of its industry peers.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -30.25
ROIC/WACCN/A
WACC8.78%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

LSTA has a Current Ratio of 5.77. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
LSTA has a Current ratio of 5.77. This is comparable to the rest of the industry: LSTA outperforms 59.89% of its industry peers.
LSTA has a Quick Ratio of 5.77. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.77, LSTA is in the better half of the industry, outperforming 61.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

LSTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.14%, which is quite good.
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LSTA will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.18% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.05%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2022 2024 2025 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LSTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as LSTA's earnings are expected to grow with 19.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.17%
EPS Next 3Y19.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LSTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LISATA THERAPEUTICS INC

NASDAQ:LSTA (12/9/2025, 1:56:52 PM)

1.94

-0.01 (-0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners8.38%
Inst Owner Change-3.69%
Ins Owners7.17%
Ins Owner Change0%
Market Cap17.11M
Revenue(TTM)1.00M
Net Income(TTM)-18.92M
Analysts82.22
Price Target13.26 (583.51%)
Short Float %0.3%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.41%
Min EPS beat(2)-1.74%
Max EPS beat(2)18.55%
EPS beat(4)3
Avg EPS beat(4)17.18%
Min EPS beat(4)-1.74%
Max EPS beat(4)29.05%
EPS beat(8)7
Avg EPS beat(8)20.12%
EPS beat(12)10
Avg EPS beat(12)-44.54%
EPS beat(16)13
Avg EPS beat(16)-29.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-37.1%
PT rev (3m)-37.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)3.89%
EPS NY rev (3m)9.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.99
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.12
BVpS2.38
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -75.21%
ROE -89.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -30.25
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
EPS Next Y9.05%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.04%
EBIT Next 3Y-10.73%
EBIT Next 5Y-1.14%
FCF growth 1Y28.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.21%
OCF growth 3YN/A
OCF growth 5YN/A

LISATA THERAPEUTICS INC / LSTA FAQ

What is the ChartMill fundamental rating of LISATA THERAPEUTICS INC (LSTA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LSTA.


Can you provide the valuation status for LISATA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to LISATA THERAPEUTICS INC (LSTA). This can be considered as Overvalued.


Can you provide the profitability details for LISATA THERAPEUTICS INC?

LISATA THERAPEUTICS INC (LSTA) has a profitability rating of 0 / 10.


Can you provide the financial health for LSTA stock?

The financial health rating of LISATA THERAPEUTICS INC (LSTA) is 6 / 10.